Andreas Tiede/ResearchGate
Dec 8, 2025, 11:08
Andreas Tiede: This Will Change Hematology Forever
Andreas Tiede, Professor, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, shared on LinkedIn:
”This will change Hematology forever: the milder Aza/Ven combination is more effective and less harmful than the traditional 3+7 chemo regimen in fit AML patients.
Groundbreaking data at ASH2025”
The American Society of Hematology Congress 2025 (ASH25) is officially underway in Orlando, Florida, from December 6 to 9.
It aims to bring together hematology professionals from across the globe.
Throughout the meeting, experts will present new research, clinical breakthroughs, and innovations that are defining the future of hematologic care.
More from ASH25 featured in Hemostasis Today.
-
Apr 24, 2026, 06:44Sandrine Meunier: Raising Awareness and Support for Hemophilia and Rare Bleeding Disorders
-
Apr 24, 2026, 06:25Octavio Marques Pontes-Neto: A Landmark Step in Stroke Prevention from The TRIDENT Trial Findings
-
Apr 24, 2026, 05:46Muhammad Alsabagh: Structured Clinical Algorithms for Pediatric and AYA Bone Marrow Failure Syndromes
-
Apr 23, 2026, 22:56Matt Simmonds: Having a Really Fabulous Time at the BSH 2026 Conference
-
Apr 23, 2026, 22:46Gloria Duah: Not All ‘O Negative’ Blood Is Safe for Every Patient
-
Apr 23, 2026, 22:46Luke McLaughlin: Is Haemophilia a Disability?
-
Apr 23, 2026, 22:44Sonia Wolf: On My Way Back From a Very Invigorating BSH
-
Apr 23, 2026, 22:43Maximo Agustin Schiavone: ‘The Lower the Better’ Is Not a Physiological Principle
-
Apr 23, 2026, 18:19Chokri Ben Lamine: Choosing the Right LMWH in Cancer Patients